Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and d... Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. Mehr anzeigen
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of...
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -4.52830188679 | 2.65 | 2.72 | 2.28 | 4039362 | 2.47138151 | CS |
| 4 | -0.17 | -6.2962962963 | 2.7 | 3.1553 | 2.28 | 2130637 | 2.55547487 | CS |
| 12 | -2.84 | -52.886405959 | 5.37 | 5.3953 | 2.28 | 1251286 | 3.04940025 | CS |
| 26 | -3.78 | -59.9049128368 | 6.31 | 8.23 | 2.28 | 933617 | 4.11614135 | CS |
| 52 | -0.26 | -9.31899641577 | 2.79 | 16.24 | 2.28 | 1226855 | 7.21233084 | CS |
| 156 | -11.95 | -82.5276243094 | 14.48 | 20.35 | 1.28 | 1116436 | 8.87210136 | CS |
| 260 | -52.22 | -95.3789954338 | 54.75 | 79.16 | 1.28 | 835583 | 11.15664117 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
